Hepatitis C virus (HCV) recurs in nearly all patients after liver transplantation. This recurrence is associated with progressive fibrosis and graft loss. It remains unclear whether the natural course of HCV recurrence is altered in patients who undergo living donor liver transplantation (LDLT). We
Is recurrence of hepatitis C worse after living donor or deceased donor liver transplantation?
β Scribed by Robert S. Brown Jr.
- Publisher
- John Wiley and Sons
- Year
- 2004
- Tongue
- English
- Weight
- 45 KB
- Volume
- 10
- Category
- Article
- ISSN
- 1527-6465
- DOI
- 10.1002/lt.20284
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## No differences between LDLT and DD Shiffman 1 23 USA, single center yes No patients developed cirrhosis on liver biopsy @ 3 years Russo 10 279 USA, UNOS database no 2-year graft survival 72% LDLT and 75% DD Bozorgzadeh 11 35 USA, single center no No difference in HCV recurrence on liver biopsy
Preliminary reports suggested that hepatitis C virus (HCV) infection has a more aggressive course following living donor liver transplantation (LDLT) compared to cadaveric liver transplantation (CLT). The aim of this prospective study was to establish if HCV disease recurrence differs between LDLT a
Hepatitis C recurs universally after liver transplantation (LT). Whether its progression differs after live donor liver transplantation (LDLT) and deceased donor liver transplantation (DDLT) is still debated. We retrospectively analyzed 201 consecutive LTs performed at our institution for hepatitis
Background. An important long-term consideration for living-donor liver transplantation (LDLT) is the expense compared with cadaveric-liver transplantation. LDLT is a more complex procedure than cadaveric transplantation and the cost of donor evaluation, donor surgery, and postoperative donor care m
In this retrospective study of hepatitis C virus (HCV)-infected transplant recipients in the 9-center Adult to Adult Living Donor Liver Transplantation Cohort Study, graft and patient survival and the development of advanced fibrosis were compared among 181 living donor liver transplant (LDLT) recip